Season 2, Episode 1

01/07/21 • 16 min

In this week’s episode, we will review a study that shows that non-invasive imaging of T cell metabolic activity can detect early graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, learn more about how detailed assessment of measurable residual disease in multiple myeloma can better define outcomes and how treatment resistance arises, and finally, examine the mechanism of action and pharmacokinetics of Ciraparantag, a small molecule being developed to rapidly reverse the effects of anticoagulants.

Previous Episode

Season 1, Episode 52

In this week’s episode, we will review a study that evaluates the role of pre-transplant leukocyte telomere length on survival outcomes in patients with myelodysplastic syndrome, learn more about a potential novel treatment for patients with WHIM syndrome, and examine a novel mechanism important for the maintenance of normal hematopoietic stem cell quiescence, and hence, long-term blood formation.

Next Episode

Season 2, Episode 2

This week’s episode covers recent research that provides new insights in erythropoiesis, mastocytosis, and chronic active EBV. First, we’ll review a report describing how interactions between an E3 ubiquitin ligase and a heterochromatin-associated protein may serve as a “toggle” of sorts to regulate the formation of red blood cells. Next, researchers find that presence of hereditary α tryptasemia may predict the risk of severe anaphylaxis in patients with mastocytosis. Finally, we’ll review a report revealing large numbers of myeloid-derived suppressor cells in patients with EBV-associated T/NK cell lymphoproliferative disorders, which may have important implications for understanding disease pathogenesis and targeted approaches to therapy.